# Primary Immunodeficiency

Weiguang Bio Advances Patient-Centric Care with Subcutaneous Immunoglobulin Trial Approval

Weiguang Biological has received NMPA approval to begin clinical trials for a subcutaneous human immunoglobulin injection. The therapy targets primary immunodeficiency diseases and represents a shift toward home-based, patient-friendly administration in the Chinese plasma market.